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ABSTRACT
High-dose chemotherapy with autologous stem cell transplantation (ASCT) is increasingly utilized in patients
with relapsed and refractory germ cell tumors (GCT). Infectious complications are common after ASCT for he-
matologic malignancies, but their epidemiology in GCT patients has not been described. To identify infectious
complications of ASCT for GCT, we conducted a retrospective study of patients treated at our institution, a ter-
tiary-care cancer center in New York City between 1994 and 2006. Patients received ciprofloxacin prophylaxis
but no routine antifungal or antiviral prophylaxis. In addition, patients were housed in shared rooms of 2 with
standard precautions during hospitalizations. Overall, 107 patients with relapsed or refractory GCT were
treated with 1-2 cycles of paclitaxel/ifosfamide and 1-3 cycles of high-dose carboplatin/etoposide with ASCT.
Sixty (56%) of 107 patients developed 95 total infections, including 33 catheter-associated bloodstream infec-
tions. Fungal, viral, and nosocomial infections were uncommon. There were no infection-related deaths. In con-
clusion, seriousmorbidity from infection is uncommon amongGCTpatients receiving high-dose chemotherapy
with ASCT. Isolation and aggressive antifungal and antiviral prophylaxis is not warranted in these patients.
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Between 20% and 30% of patients with metastatic
germ cell tumor (GCT) either fail to achieve a com-
plete response or relapse after treatment with etopo-
side and cisplatin, with or without bleomycin [1,2].
The curative potential of conventional-dose therapy
in these patients is primarily limited to those who re-
lapse after a first complete response [3]. In contrast,
high-dose regimens containing carboplatin and etopo-
side may cure 50%-60% of patients with relapsed or
refractory disease, even in a third or later remission
[4,5]. These latter regimens are dose-dense, involving
up to 3 cycles of chemotherapy and autologous stemcell transplantation (ASCT) within 9-12 weeks. The
infectious complications resulting from this approach
have not been previously described [6].
Guidelines to prevent infection among patients
with cancer [7], and specifically those undergoing
ASCT [8], are widely utilized. Data to support these
guidelines derive primarily from patients treated
for hematologic malignancies. Thus, it is unclear
whether the guidelines pertain to patients with GCT.
To determine the appropriate strategies for preventing
infection in patients with GCT receiving high-dose
chemotherapy and ASCT, we reviewed the infectious
complications in a large single-center cohort.595
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Medical, laboratory, and pharmacy records, as well
as ICD-9 data, were reviewed for all patients on an in-
stitutional review board-approved trial of high-dose
chemotherapy (TICE) at Memorial Sloan- Kettering
Cancer Center (MSKCC) from 1/1/1994-12/31/
2006. As previously described [4,9], treatment con-
sisted of 2 14- to 21-day cycles of paclitaxel 200 mg/
m2 on day 1 and ifosfamide 2 gm/m2 on days 2-4, fil-
grastim beginning day 5, and peripheral blood stem
cell collection on days 11-13. Subsequent treatment
consisted of 3 21- to 28-day cycles of carboplatin dosed
to an area under the curve (AUC) of 12-28mg/mL2min
on days 1-3, and etoposide 400mg/m2 on days 1-3, fol-
lowed by ASCT on day 5, and filgrastim beginning day
5 [4]. All patients received oral ciprofloxacin between
days 7 and 11 of the paclitaxel/ifosfamide cycles and
days 6 and 10 of the carboplatin/etoposide cycles.
No antifungal, antiviral, or Pneumocystis-directed pro-
phylaxis was given. Patients were only hospitalized on
days 1-5 of each cycle and upon developing complica-
tions that required hospitalization. During hospitali-
zations, patients were routinely placed in 2-person
shared rooms with standard precautions (ie, no gloves,
gown, or mask).
All infectious episodes occurring between day 1 of
the first cycle of TICE and day 28 of the last cycle were
noted, except superficial infections (ie, oropharyngeal
candidiasis, folliculitis, and onychomycosis). Time to
first infection was calculated from the first day of cycle
1 until first documented infection or day 28 of the last
cycle for those who did not develop an infection. The
Fisher exact test was used to compare categoric vari-
ables, the Wilcoxon rank sum test for continuous vari-
ables, and Kaplan-Meier methods to estimate time to
infection.
RESULTS
Between 1994 and 2006, 107 patients with relapsed
or refractory germ cell tumor were treated with TICE
at our institution (Table 1) [4,9]. Two patients re-
ceived only 1 cycle of paclitaxel/ifosfamide, as .6 
106/kg CD341 cells were collected during the first
cycle.
Between the beginning of cycle 1 and day 28 of the
last cycle, 60 (56%) of 107 patients developed a total of
95 infections, and 47 (44%) patients had no infections
(Table 2 and Figure 1). A comparison of patient char-
acteristics failed to identify risk factors for developing
infection (Table 3).
Overall, 82% of infections occurred during the
carboplatin/etoposide cycles, with the highest rate
during the first carboplatin/etoposide cycle (Figure 1
and Table 2). Infection resulted in a treatment delay
after 25 of 483 total (5.2%) cycles, including 6 of 212(2.8%) taxol/ifosfamide versus 19 of 271 (7.0%) carbo-
platin/etoposide cycles (P\ .05). Five patients were
removed from the treatment protocol because of infec-
tious complications, all during carboplatin/etoposide
cycles (Table 4). Infection did not contribute to mor-
tality in any patients within 100 days after completion
of the final TICE cycle. In addition, survival at 1 year
after beginning the first cycle was similar for patients
who experienced an infection (68%) and those who
did not (64%).
Specific Infections
The most common infectious complication was
central venous catheter-associated bloodstream infec-
tion, which prompted catheter removal in 24 (73%)
of 33 cases. Six episodes were polymicrobial. One
additional bloodstream infection, caused byMicrococcus
spp, developed in a patient with a tonsillar abscess.
Overall, 32 (76%) of 42 blood isolates were Gram-
positive, including 16 (50%) that were resistant to
methicillin (Table 5). Although ciprofloxacin was re-
peatedly used for prophylaxis, 8 (80%) of 10 Gram-
negative isolates were susceptible to ciprofloxacin.
Susceptibilities were available against levofloxacin
and ciprofloxacin for 35 isolates, of which 21 (60%)
Table 1. Characteristics of Study Patients (N 5 107)
Characteristic Patients No. (%)
Male 104 (97)
Median age (range) 32 (16-54)
Histology
Nonseminoma 94 (88)
Seminoma 13 (12)
Primary site
Gonadal 75 (70)
Mediastinum 21 (20)
Retroperitoneum 5 (5)
Unknown 4 (4)
Pineal gland 2 (2)
Metastatic sites
Lung 67 (63)
Retroperitoneum 61 (57)
Mediastinum 47 (44)
Other lymph nodes 28 (26)
Liver 24 (22)
Bone 8 (7)
Supraclavicular lymph node 3 (3)
No. of disease sites
1 29 (27)
2 32 (30)
. 3 46 (43)
No. of prior cisplatin regimens
0 1 (1)
1 75 (70)
2 29 (27)
3 2 (2)
All study patients had received high-dose chemotherapy and autolo-
gous stem cell transplantation for relapsed or refractory germ cell
tumors (GCT).
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for ciprofloxacin (P 5 NS).
There were 11 episodes of Clostridium difficile coli-
tis (detected by stool cytotoxicity assay): 8 developed
after the institution of broad-spectrum antibiotics for
fever and neutropenia. AllClostridium difficile infections
responded to antimicrobial therapy, but 3 patients
relapsed and required a second course of treatment.
The incidence of Clostridium difficile colitis did not
change significantly over the study period.
One patient developed a possible invasive fungal
pneumonia [10] on day 15 of carboplatin/etoposide
cycle #3, manifested as fever and nodular infiltrates.
The findings resolved after empiric treatment with
voriconazole. There were 3 cases of varicella zoster,
including 2 with multidermatomal involvement and
1 case of Ramsay-Hunt Syndrome. All 3 patients
were treated successfully with acyclovir and none de-
veloped postherpetic neuralgia. One patient from
Ecuador was found to have Strongyloides in his stool
during a work up for diarrhea during paclitaxel/ifos-
famide cycle #2 and was treated with successfully
with ivermectin. He had no evidence of dissemination
or hyperinfection.
Fever and Neutropenia
Fever and neutropenia was more common during
carboplatin/etoposide cycles than paclitaxel/ifosfa-
mide cycles (57% versus 20% of cycles; P \ .01).
Interestingly, fever and neutropenia was less com-
mon during the first carboplatin/etoposide cycle
among the 33 patients who were admitted for fever
and neutropenia during the paclitaxel/ifosfamide cy-
cles than the 67 patients who were not previously
admitted for fever and neutropenia (52% versus
69%; P \ .05).
Table 2. Infectious Complications in Study Patients (N 5 107)
Clinical Syndromes
Paclitaxel/Ifosfamide Carboplatin/Etoposide
Total infections
(laboratory-confirmed)
Cycle 1
(N 5 107)
Cycle 2
(n 5 105)
Cycle 1
(n 5 100)
Cycle 2
(n 5 92)
Cycle 3
(n 5 79)
Hospitalized for fever
and neutropenia
29 (27%) 14 (13%) 63 (63%) 51 (55%) 41 (52%) NA
Catheter-associated bloodstream
infection
2 3 15 7 6 33 (33)
Cellulitis 3 1 4 2 5 15 (3)
C. difficile colitis 0 0 6 3 2 11 (11)
Bacterial pneumonia 2 2 3 0 0 7 (0)
Neutropenic enterocolitis 0 0 1 2 2 5 (0)
Urinary tract infection 1 0 1 1 0 3 (3)
Varicella zoster 0 0 1 1 1 3 (3)
Otitis media 0 0 1 0 1 2 (0)
Perirectal abscess 0 0 0 2 0 2 (1)
Cutaneous abscess 0 0 2 0 0 2 (1)
Candida esophagitis 0 0 0 1 1 2 (0)
Odontogenic abscess 1 0 1 0 0 2 (0)
Herpes Simplex 0 0 1 0 1 2 (2)
Streptococcal pharyngitis 0 0 0 0 1 1 (1)
Otitis externa 0 1 0 0 0 1 (1)
Strongyloides enteritis 0 1 0 0 0 1 (1)
Influenza A virus 0 0 0 1 0 1 (1)
Possible fungal pneumonia 0 0 0 0 1 1 (0)
Tonsillar abscess
with bacteremia
0 0 1 0 0 1 (1)
Cases/total, No. 9 (8%) 8 (8%) 37 (37%) 20 (22%) 21 (27%) 95 (62)
Study patients had relapsed or refractory GCT treated with high-dose chemotherapy and autologous stem cell transplantation. Infections that
were not laboratory-confirmed were diagnosed based on clinical presentation.
Figure 1. Time to first infection among study patients. All patients
who did not develop an infection after 5 cycles were censored 140
days after beginning the first cycle.
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Infection is a major cause of morbidity and mortal-
ity among patients with hematologic malignancies
who undergo high-dose chemotherapy with stem cell
transplantation [11-13]. Although neutropenic fever
and infection were common among our GCT patients,
all infections were successfully treated, and there was
no infection-associated mortality.
Patient Isolation
Guidelines developed by the US Centers for Dis-
ease Control, Infectious Disease Society of America,
and the American Society for Blood and Marrow
Transplantation, recommend housing ASCT recipi-
ents in private hospital rooms [8]. This increases the
cost of ASCT and limits its use at hospitals with lim-
ited space. Since the 1980s, we have routinely housed
GCT patients receiving TICE and ASCT at our insti-
tution in shared rooms, and employ only standard pre-
cautions, except in patients who already require
isolation. In our series, no infections caused by patho-
gens specifically associated with nosocomial exposure
(eg, methicillin-resistant Staphylococcus aureus, vanco-
mycin-resistant Enterococcus) were observed. In addi-
tion, only 1 patient developed a documented
respiratory viral infection, and this may have been ac-
quired in the community. Thus, a private room ap-
pears to be unnecessary for patients at low risk for
infectious mortality during ASCT, such as those with
GCT.
Antimicrobial Prophylaxis
National Comprehensive Cancer Network [7]
guidelines recommend prophylaxis with acyclovir for
ASCT recipients. In our series, infection caused by
herpes viruses occurred in\5% of patients and Can-
dida infection developed in \2% of patients. These
rates were significantly lower than those from previous
Table 3. Characteristics Associated with Infection among Study Patients
Receiving TICE with ASCT
Characteristic
Infection Present
(n 5 60), No. (%)
No Infection
(n 5 47), No. (%) P
Male sex 58 (97) 46 (98) .99
Ethnicity
White 52 (87) 41 (87) .99
Other 8 (13) 6 (13)
Median age (range) 28 (17-52) 34 (16-54) .12
Prior therapy
Hormonal (n 5 102) 3 (5) 3 (6) .99
Immunotherapy
(n 5 102)
3 (5) 3 (6) .99
Radiation (n 5 97) 8 (12) 3 (8) .48
Surgery 58 (97) 43 (91) .40
# 6 previous
cycles of cisplatin
51 (85) 41 (87) .77
Received all cycles
of TICE
42 (70) 37 (79) .38
TICE indicates paclitaxel/ifosfamide and carboplatin/etoposide;
ASCT, autologous stem cell transplantation
Table 4.Outcomes in Patients Removed from Protocol Because of Infectious
Complications (n 5 5)
Patient Infectious Complication Outcome
1 Removed from protocol after
second cycle of carboplatin/
etoposide because of
methicillin-resistant
Staphylococcus aureus
cellulitis. Patient declined
retroperitoneal lymph node
dissection.
Died 8 months after
removal from
protocol*
2 Removed from protocol after
second cycle of carboplatin/
etoposide as a result of
perirectal abscess.
Died 15 months after
removal from
protocol*
3 Removed from protocol after
second cycle of carboplatin/
etoposide as a result of
perirectal abscess.
Alive 23 months after
removal from
protocol.
4 Removed from protocol after
first cycle of carboplatin/
etoposide as a result of urinary
tract infection and central
venous catheter-associated
bloodstream infection.
Alive 26 months after
removal from
protocol.
5 Removed from protocol after
first cycle of carboplatin/
etoposide as a result of central
venous catheter-associated
bloodstream infection
Died 10 months after
removal from
protocol.*
*All 3 deaths resulted from progressive germ cell tumor (GCT).
Table 5. Isolates (n 5 42) from Bloodstream Infections among Study
Patients
Pathogen No. %
Gram positive 32 76.2%
Coagulase-negative Staphylococcus 16 38.1%
Streptococcus viridians 6 14.3%
Micrococcus sp. 4 9.5%
Bacillus sp. 2 4.8%
Streptococcus agalactiae 1 2.4%
Staphylococcus aureus,
methicillin-sensitive
1 2.4%
Streptococcus pyogenes 1 2.4%
Corynebacterium jeikeium 1 2.4%
Gram negative 10 23.8%
Serratia marcescens 3 7.1%
Klebsiella pneumoniae 2 4.8%
Pseudomonas aeruginosa 1 2.4%
Burkholderia cepacia 1 2.4%
Comamonas acidovorans 1 2.4%
Acinetobacter lwoffii 1 2.4%
Anaerobic Gram-negative
rod, unspeciated
1 2.4%
Total 42 100
The total number of isolates exceeds the number of bloodstream
infections (n 5 34) as 6 infections were polymicrobial.
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of patients with breast cancer [16]. All viral and fungal
infections completely resolved with appropriate ther-
apy and did not require removal from the study. Based
on the limited morbidity of these infections in our se-
ries and the potential for adverse effects from prophy-
laxis, we do not routinely give antifungal or antiviral
prophylaxis to patients receiving TICE and ASCT.
Two randomized studies and a meta-analysis have
demonstrated abenefit for fluoroquinoloneprophylaxis
during chemotherapy-induced neutropenia [17-19].
Our patients received ciprofloxacin prophylaxis, which
provides limited activity against Gram-positive patho-
gens and may have contributed to the high proportion
of bloodstream infections caused by these organisms.
We recently switched standard prophylaxis for patients
receiving TICE from ciprofloxacin to levofloxacin,
which offers a greater spectrum of activity against
Gram-positive pathogens. Of concern, fluoroquino-
lone use has been associated with increasing rates of
Clostridium difficile colitis [14]. Despite multiple cycles
of ciprofloxacin prophylaxis, Clostridium difficile colitis
occurredduring only11 (2%)of 483 cycles in our series,
similar to previous studies of levofloxacin prophylaxis
[20] and ASCT for hematologic malignancies [21].
Fever and Neutropenia
Fever and neutropenia in patients receiving TICE
is treated at our Center with 2 agents active against
Gram-negative pathogens, typically an antipseudomo-
nal beta-lactam and a fluoroquinolone. If possible, we
avoid aminoglycosides during TICE, as their potential
ototoxicity may compound hearing loss in these pa-
tients [4]. Of note, 80% of Gram-negative blood iso-
lates were ciprofloxacin-susceptible, so this approach
is likely to be adequate, even with fluoroquinolone
prophylaxis.
Based on the results of this study, we now routinely
use empiric vancomycin in addition to 2 agents active
against Gram-negative organisms in patients with fe-
ver and neutropenia during TICE. Of 198 hospital ad-
missions for fever and neutropenia in this study, 16
(8%) were associated with a bloodstream infection
caused by a methicillin-resistant, Gram-positive or-
ganism. If blood cultures fail to grow an organism re-
quiring vancomycin within 48 hours, the vancomycin
is discontinued. Of note, all patients receiving TICE
have leukopheresis catheters, which may place them
at high risk for developing a bloodstream infection.
The higher rates of fever and neutropenia during
the carboplatin/etoposide cycles versus the paclitaxel/
ifosfamide cycles was not unexpected given the greater
intensity ofmyelosuppression during these cycles. Sur-
prisingly, admission for an episode of fever and neutro-
penia during the taxol/ifosfamide cycles seemed to
decrease the likelihood for admission for fever andneutropenia following the first carboplatin/etoposide
cycle. Reasons for this are not clear, but may relate to
debulking of the bacterial load in the gastrointestinal
tract by prior courses of broad spectrum antibiotics.
In conclusion, high-dose chemotherapy with
ASCT for relapsed or refractory GCT is associated
with a notable lack of severe infectious complications.
Despite high rates of neutropenic fever and central
venous catheter-related infections, infectious compli-
cations do not appear to influence overall outcome.
Prompt evaluation and management of infectious syn-
dromes, rather than patient isolation and prophylaxis,
appears to be the best strategy for minimizing infec-
tious morbidity in ASCT recipients at low risk, such
as those receiving TICE.
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